基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
过继性自然杀伤(NK)细胞疗法是治疗三阴性乳腺癌的一种有前景的策略,但其疗效往往受到瘤内持久性差以及在免疫抑制性肿瘤微环境中功能耗竭的限制。
英文原题:Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.
我们的结果表明,NAC后TIL富集的TNBC患者复发风险更高。
背景:三阴性乳腺癌(TNBC)患者除非在新辅助化疗(NAC)后达到病理完全缓解(pCR),否则预后较差。很少有研究分析剂量密集剂量增强(dd-di)NAC后TIL水平的变化。患者与方法:2009年至2018年,117例TNBC患者在我们机构接受了dd-di NAC。我们旨在确定与NAC前和NAC后TIL水平相关的因素,以及肿瘤学结局无复发生存期(RFS)和总生存期(OS)。结果:NAC前和NAC后TIL水平的中位数分别为15%和3%。治疗引起的TIL水平变化与代谢反应(SUV)和pCR显著相关。高NAC后TIL水平与两周期NAC后代谢反应较弱、NAC完成时存在残留病灶和淋巴结受累相关。在多变量分析中,高NAC后TIL水平独立预测较差的RFS和较差的OS(每增加10%的HR = 1.4,95%CI(1.1;1.9)p = 0.014,以及每增加10%的HR = 1.8,95%CI(1.3 2.3),p < 0.0001)。结论:我们的结果表明,NAC后TIL富集的TNBC患者复发风险更高。这些患者是临床试验中辅助治疗(如免疫治疗)的潜在候选者。
Background: Patients with triple-negative breast cancers (TNBC) have a poor prognosis unless a pathological complete response (pCR) is achieved after neoadjuvant chemotherapy (NAC). Few studies have analyzed changes in TIL levels following dose-dense dose-intense (dd-di) NAC. Patients and methods: From 2009 to 2018, 117 patients with TNBC received dd-di NAC at our institution. We aimed to identify factors associated with pre- and post-NAC TIL levels, and oncological outcomes relapse-free survival (RFS), and overall survival (OS). Results: Median pre-NAC and post-NAC TIL levels were 15% and 3%, respectively. Change in TIL levels with treatment was significantly correlated with metabolic response (SUV) and pCR. High post-NAC TIL levels were associated with a weak metabolic response after two cycles of NAC, with the presence of residual disease and nodal involvement at NAC completion. In multivariate analyses, high post-NAC TIL levels independently predicted poor RFS and poor OS (HR = 1.4 per 10% increment, 95%CI (1.1; 1.9) p = 0.014 and HR = 1.8 per 10% increment 95%CI (1.3 2.3), p < 0.0001, respectively). Conclusion: Our results suggest that TNBC patients with TIL enrichment after NAC are at higher risk of relapse. These patients are potential candidates for adjuvant treatment, such as immunotherapy, in clinical trials.
MEMBER ACCOUNT
登录成功会直接打开下一页。